New finding of nalbuphine metabolites in men

NMR spectroscopy and UPLC-MS/MS spectrometry assays in a pilot human study

Hong Jaan Wang, Cheng Huei Hsiong, Li Heng Pao, Wen Liang Chang, Li Jie Zhang, Min Jen Lin, Shung Tai Ho, Pei Wei Huang, Oliver Yoa Pu Hu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A safe and efficient semi-synthetic narcotic nalbuphine (NAL) which was broadly applied in analgesic therapy has long been considered to eliminate from human body via phase II conjugation. However, up to the present, neither the complete metabolic pathways nor the identified metabolites of NAL have been clarified in documented reports. In this study, four novel metabolites were discovered by incubating NAL with human liver microsomes. These metabolites were later quantified in blood samples from human volunteers treated with NAL. An accurate and precise new method for simultaneously determining NAL and its metabolites was also established. Their chemical structures were elucidated on the basis of one- and two-dimensional NMR spectroscopic analyses including 1H-1H correlation spectroscopy, nuclear overhauser enhancement spectroscopy, heteronuclear single-quantum correlation, and heteronuclear multiple bond correlation, and further confirmed by mass spectrometry. The analytical method was validated and applied successfully to a pilot human study with ultra-high performance liquid chromatography-tandem mass spectrometry employed with positive ion electrospray ionization via multiple reaction monitoring mode. This is the first report on the qualitative and quantitative analysis of NAL coupled with its two hydroxylated (3′-hydroxynalbuphine and 4′-hydroxynalbuphine) and two conjugated metabolites (nalbuphine-3-β-d-glucuronide and nalbuphine-6-β-d-glucuronide). The present method offers a rapid and simple way of performing pharmacokinetic studies of NAL, and assists in elucidating its metabolic pathway in humans.

Original languageEnglish
Pages (from-to)709-718
Number of pages10
JournalMetabolomics
Volume10
Issue number4
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Nalbuphine
Metabolites
Spectrometry
Nuclear magnetic resonance spectroscopy
Assays
Spectrum Analysis
Magnetic Resonance Spectroscopy
Glucuronides
Metabolic Networks and Pathways
Mass spectrometry
Spectroscopy
Electrospray ionization
Pharmacokinetics
Narcotics
High performance liquid chromatography
Liver Microsomes
Tandem Mass Spectrometry
Human Body
Liver
Analgesics

Keywords

  • Metabolite
  • Nalbuphine
  • NMR
  • P450
  • UGT
  • UPLC-MS/MS

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Wang, H. J., Hsiong, C. H., Pao, L. H., Chang, W. L., Zhang, L. J., Lin, M. J., ... Hu, O. Y. P. (2014). New finding of nalbuphine metabolites in men: NMR spectroscopy and UPLC-MS/MS spectrometry assays in a pilot human study. Metabolomics, 10(4), 709-718. https://doi.org/10.1007/s11306-013-0605-y

New finding of nalbuphine metabolites in men : NMR spectroscopy and UPLC-MS/MS spectrometry assays in a pilot human study. / Wang, Hong Jaan; Hsiong, Cheng Huei; Pao, Li Heng; Chang, Wen Liang; Zhang, Li Jie; Lin, Min Jen; Ho, Shung Tai; Huang, Pei Wei; Hu, Oliver Yoa Pu.

In: Metabolomics, Vol. 10, No. 4, 01.01.2014, p. 709-718.

Research output: Contribution to journalArticle

Wang, HJ, Hsiong, CH, Pao, LH, Chang, WL, Zhang, LJ, Lin, MJ, Ho, ST, Huang, PW & Hu, OYP 2014, 'New finding of nalbuphine metabolites in men: NMR spectroscopy and UPLC-MS/MS spectrometry assays in a pilot human study', Metabolomics, vol. 10, no. 4, pp. 709-718. https://doi.org/10.1007/s11306-013-0605-y
Wang, Hong Jaan ; Hsiong, Cheng Huei ; Pao, Li Heng ; Chang, Wen Liang ; Zhang, Li Jie ; Lin, Min Jen ; Ho, Shung Tai ; Huang, Pei Wei ; Hu, Oliver Yoa Pu. / New finding of nalbuphine metabolites in men : NMR spectroscopy and UPLC-MS/MS spectrometry assays in a pilot human study. In: Metabolomics. 2014 ; Vol. 10, No. 4. pp. 709-718.
@article{bf220862b35c45abaa3d34caa768fcdf,
title = "New finding of nalbuphine metabolites in men: NMR spectroscopy and UPLC-MS/MS spectrometry assays in a pilot human study",
abstract = "A safe and efficient semi-synthetic narcotic nalbuphine (NAL) which was broadly applied in analgesic therapy has long been considered to eliminate from human body via phase II conjugation. However, up to the present, neither the complete metabolic pathways nor the identified metabolites of NAL have been clarified in documented reports. In this study, four novel metabolites were discovered by incubating NAL with human liver microsomes. These metabolites were later quantified in blood samples from human volunteers treated with NAL. An accurate and precise new method for simultaneously determining NAL and its metabolites was also established. Their chemical structures were elucidated on the basis of one- and two-dimensional NMR spectroscopic analyses including 1H-1H correlation spectroscopy, nuclear overhauser enhancement spectroscopy, heteronuclear single-quantum correlation, and heteronuclear multiple bond correlation, and further confirmed by mass spectrometry. The analytical method was validated and applied successfully to a pilot human study with ultra-high performance liquid chromatography-tandem mass spectrometry employed with positive ion electrospray ionization via multiple reaction monitoring mode. This is the first report on the qualitative and quantitative analysis of NAL coupled with its two hydroxylated (3′-hydroxynalbuphine and 4′-hydroxynalbuphine) and two conjugated metabolites (nalbuphine-3-β-d-glucuronide and nalbuphine-6-β-d-glucuronide). The present method offers a rapid and simple way of performing pharmacokinetic studies of NAL, and assists in elucidating its metabolic pathway in humans.",
keywords = "Metabolite, Nalbuphine, NMR, P450, UGT, UPLC-MS/MS",
author = "Wang, {Hong Jaan} and Hsiong, {Cheng Huei} and Pao, {Li Heng} and Chang, {Wen Liang} and Zhang, {Li Jie} and Lin, {Min Jen} and Ho, {Shung Tai} and Huang, {Pei Wei} and Hu, {Oliver Yoa Pu}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11306-013-0605-y",
language = "English",
volume = "10",
pages = "709--718",
journal = "Metabolomics",
issn = "1573-3882",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - New finding of nalbuphine metabolites in men

T2 - NMR spectroscopy and UPLC-MS/MS spectrometry assays in a pilot human study

AU - Wang, Hong Jaan

AU - Hsiong, Cheng Huei

AU - Pao, Li Heng

AU - Chang, Wen Liang

AU - Zhang, Li Jie

AU - Lin, Min Jen

AU - Ho, Shung Tai

AU - Huang, Pei Wei

AU - Hu, Oliver Yoa Pu

PY - 2014/1/1

Y1 - 2014/1/1

N2 - A safe and efficient semi-synthetic narcotic nalbuphine (NAL) which was broadly applied in analgesic therapy has long been considered to eliminate from human body via phase II conjugation. However, up to the present, neither the complete metabolic pathways nor the identified metabolites of NAL have been clarified in documented reports. In this study, four novel metabolites were discovered by incubating NAL with human liver microsomes. These metabolites were later quantified in blood samples from human volunteers treated with NAL. An accurate and precise new method for simultaneously determining NAL and its metabolites was also established. Their chemical structures were elucidated on the basis of one- and two-dimensional NMR spectroscopic analyses including 1H-1H correlation spectroscopy, nuclear overhauser enhancement spectroscopy, heteronuclear single-quantum correlation, and heteronuclear multiple bond correlation, and further confirmed by mass spectrometry. The analytical method was validated and applied successfully to a pilot human study with ultra-high performance liquid chromatography-tandem mass spectrometry employed with positive ion electrospray ionization via multiple reaction monitoring mode. This is the first report on the qualitative and quantitative analysis of NAL coupled with its two hydroxylated (3′-hydroxynalbuphine and 4′-hydroxynalbuphine) and two conjugated metabolites (nalbuphine-3-β-d-glucuronide and nalbuphine-6-β-d-glucuronide). The present method offers a rapid and simple way of performing pharmacokinetic studies of NAL, and assists in elucidating its metabolic pathway in humans.

AB - A safe and efficient semi-synthetic narcotic nalbuphine (NAL) which was broadly applied in analgesic therapy has long been considered to eliminate from human body via phase II conjugation. However, up to the present, neither the complete metabolic pathways nor the identified metabolites of NAL have been clarified in documented reports. In this study, four novel metabolites were discovered by incubating NAL with human liver microsomes. These metabolites were later quantified in blood samples from human volunteers treated with NAL. An accurate and precise new method for simultaneously determining NAL and its metabolites was also established. Their chemical structures were elucidated on the basis of one- and two-dimensional NMR spectroscopic analyses including 1H-1H correlation spectroscopy, nuclear overhauser enhancement spectroscopy, heteronuclear single-quantum correlation, and heteronuclear multiple bond correlation, and further confirmed by mass spectrometry. The analytical method was validated and applied successfully to a pilot human study with ultra-high performance liquid chromatography-tandem mass spectrometry employed with positive ion electrospray ionization via multiple reaction monitoring mode. This is the first report on the qualitative and quantitative analysis of NAL coupled with its two hydroxylated (3′-hydroxynalbuphine and 4′-hydroxynalbuphine) and two conjugated metabolites (nalbuphine-3-β-d-glucuronide and nalbuphine-6-β-d-glucuronide). The present method offers a rapid and simple way of performing pharmacokinetic studies of NAL, and assists in elucidating its metabolic pathway in humans.

KW - Metabolite

KW - Nalbuphine

KW - NMR

KW - P450

KW - UGT

KW - UPLC-MS/MS

UR - http://www.scopus.com/inward/record.url?scp=84904397135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904397135&partnerID=8YFLogxK

U2 - 10.1007/s11306-013-0605-y

DO - 10.1007/s11306-013-0605-y

M3 - Article

VL - 10

SP - 709

EP - 718

JO - Metabolomics

JF - Metabolomics

SN - 1573-3882

IS - 4

ER -